Hamlet Pharma AB

Hamlet Pharma AB

  • Price (SEK)2.80
  • Today's Change0.02 / 0.72%
  • Shares traded21.43k
  • 1 Year change-33.01%
  • Beta--
Data delayed at least 15 minutes, as of Jun 01 2023.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Hamlet Pharma AB is a Sweden-based company that develops cancer therapeutics. The Company develops cancer therapeutics based on research into protein complexes that selectively induce cell-death in tumours. HAMLET, which stands for Human Alpha-lactalbumin Made LEthal to Tumours, is a protein-fatty acid complex derived from human milk. The complex induces apoptosis in tumour cells while leaving normal cells unaffected. In laboratory experiments, HAMLET is active against many different types of tumour cells, and uses several mechanisms to trigger cell death. HAMLET is also being evaluated clinically on skin papillomas and on bladder cancers. Alpha1H is a Company’s drug candidate for bladder cancer in ongoing phase I/II clinical trials.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-17.20m
  • Incorporated--
  • Employees4.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Vivesto AB1.02m-359.69m155.76m20.00--0.5107--153.46-0.7154-0.71540.0020.56680.0022.360.1856,388.89-69.70---74.00---1,048.77---35,437.54--6.20--0.0252---96.12---175.55------
Bioextrax AB publ701.53k-20.17m159.65m----5.75--227.57-1.10-1.100.03631.090.0359--1.71---103.28---124.18---93.29---2,875.81------0.00--43.24---77.24------
Bactiquant A/S19.36m-22.16m164.60m----7.36--8.50-0.7607-0.76070.66450.73060.51954.232.95---59.48-28.60-68.98-32.61-9.30---114.50-55.762.78-26.930.2479--48.20---4.66------
Annexin Pharmaceuticals AB (publ)0.00-41.38m165.10m4.00--8.24-----0.2716-0.27160.000.12380.00-------123.07-111.82-144.39-132.67-----------20,689.000.00------21.89------
StenoCare A/S7.01m-25.47m168.57m----3.86--24.03-1.32-1.320.36292.000.1075--2.48---39.03---46.47-------363.13--1.16-12.940.1776--137.54---28.04------
Xintela AB0.00-66.22m186.59m----13.84-----0.3955-0.39550.000.01880.000.00-----257.29-145.61-1,598.87-254.80-------14,755.581.01-16.830.00-------11.20--54.98--
Moberg Pharma AB (publ)207.00k-16.30m186.79m----0.344--902.37-1.88-1.880.023153.840.0004--0.0348---3.25---3.36--100.00---7,873.43------0.0091-----78.392.40------
Orphazyme A/S0.00-59.86m191.73m1.00--2.95-----1.090.73920.001.180.00----0.00-33.12-66.58-89.20-85.98------------0.00------51.19------
Hamlet Pharma AB0.00-17.20m201.05m4.00--8.14-----0.1569-0.15690.000.34390.00-------63.13-88.40-84.36-115.77-----------226.20---------122.71------
ExpreS2ion Biotech Holding AB6.66m-131.08m211.04m28.00--2.03--31.68-3.36-3.360.1722.110.0548--5.19222,066.70-107.81-58.88-120.43-69.62-208.6925.33-1,967.53-394.75----0.0547---55.21-8.89-170.02--13.21--
Lifecare AS21.65m-17.09m228.23m----4.22--10.54-0.148-0.1480.18780.46880.4332--30.31---34.20-41.60-39.09-47.04-----78.96-147.96----0.00--1,284.20109.30-10.08------
Kancera AB0.00-57.98m233.92m7.00--2.55-----1.01-,023.47---78.970.00-------14.88------
Abliva AB31.00k-79.33m238.72m6.00--1.60--7,700.76-0.1162-0.11620.000040.14110.0003--0.0015,166.67-72.67-73.09-81.76-85.88-----255,896.80-78,072.63---37.560.00---79.472.8030.96---26.59--
Active Biotech AB publ0.00-54.17m242.37m11.00--10.55-----0.218-0.2180.000.08680.00-------132.45-33.26-185.84-77.75-------600.70----0.1513-------17.15------
Arctic Bioscience AS33.52m-33.27m248.10m----0.8485--7.40-1.40-1.401.4111.790.10240.70723.24---10.17---11.20--33.98---99.28--4.03--0.00--59.29--20.09------
Data as of Jun 01 2023. Currency figures normalised to Hamlet Pharma AB's reporting currency: Swedish Krona SEK

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Skandia Investment Management ABas of 30 Sep 2021877.05k0.00%
Svenska Handelsbanken AB (Private Banking)as of 30 Sep 2021290.65k0.00%
Data from 31 Mar 2023 - 30 Apr 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.